The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
|Articles|September 29, 2021
Treatment Considerations in Relapsed/Refractory Multiple Myeloma
Advertisement
This article discusses the current treatment landscape and therapeutic strategies for multiple myeloma as well as the various factors that influence treatment selection including a patient’s ability to tolerate therapy, treatment goals, line of therapy, nature of relapse, duration and depth of response, and adverse events from previous therapies.
Advertisement
Related to this article
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Roswell Park Comprehensive Cancer Center unveiled a new and more compact mobile lung cancer screening unit.
Advertisement
Advertisement
Trending on OncLive
1
OSE2101 Plus Pembrolizumab as Maintenance Boosts PFS in Platinum-Sensitive Ovarian Cancer
2
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
3
The OncFive: Top Oncology Articles for the Week of 9/14/2026
4
FDA Grants Breakthrough Therapy Designation to First-Line Daraxonrasib Plus Chemo in mPDAC
5